Back to News
Market Impact: 0.2
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
Source: businesswire.com
Healthcare & BiotechProduct Launches
JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in Kuwait. The announcement adds an authorized market for the therapy; no sales projections or financial impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Razer’s CEO waited 20 years for everyone to become a gamer. He says AI is finally making it happen
- Tech giants race to get AI gadgets on shelves for holiday rush
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Electric vehicle sales in the U.S. are showing signs of life
- Delta knows the top 40% of Americans are $40 trillion richer than just a few years ago. Cue new burgers and bourbon on Delta One’s biggest revamp yet